Spring greetings! We hope you are all hanging in there with sheltering in place, home schooling and social distancing. Keep the faith that there is light at the end of the tunnel. This is a perfect time to celebrate FOOD ALLERGY AWARENESS WEEK. Sponsored by Food Allergy Research & Education (FARE), it runs from MAY 10th through the 16th. Simply click on the above link for a schedule of numerous webinars and Facebook Live seminars. Topics include oral immunotherapy, the latest research, introducing peanut foods to infants, and a Top 9-Free Meal Challenge.
Meanwhile, stay well and enjoy the warmer weather!
This story about the death of Dillon Mueller of Wisconsin reminds us of Ruthie T. Cornell, our founder Jon Terry’s sister. She also died from a bee sting and did not know she was allergic. Like George and Angel Mueller, we have worked tirelessly to have legislation enacted. We want everyone from bus drivers to first responders and restaurant workers to have access to non-patient specific epinephrine. And just like Dillon’s parents, we conduct training sessions for anyone who wants to learn what to do in an anaphylaxis emergency and how to use an epinephrine auto-injector (EAI) device. Dillon’s family knows of at least 7 people whose lives were saved because of their efforts.
Dillon Mueller Memorial Fund Helps Save Lives
Fund Helps Increase Availability of Epinephrine in Wisconsin
COVID-19 has certainly brought to everyone’s attention that people with asthma are at a greater risk of severe illness and hospitalization if they contract the virus. The Asthma and Allergy Foundation of America (AAFA) and the MedicAlert Foundation have joined forces to develop an online asthma or anaphylaxis treatment plan that will be part of a MedicAlert member’s health profile. In an emergency, MedicAlert will relay the action plan and other critical medical information to first responders to ensure fast and accurate treatment. If you have asthma or a life-threatening allergy, now is the time to get yourself a MedicAlert ID!
Washington, D.C., May 05, 2020 (GLOBE NEWSWIRE) -- Over 65 million people in the United States live with asthma or allergies to food, drugs or other allergens. Tragically, 3,600 people die each year from asthma – deaths that are often preventable. COVID-19 poses additional danger to these populations. Two leading non-profits have joined forces to raise awareness and provide resources for living with these potentially life-threatening conditions: asthma and anaphylaxis.
FARE (Food Allergy Research & Education) is proud to announce a new initiative called “Baby’s First” that hopes to reduce the number of children who have food allergies. New and soon-to-be parents will have access to all the best information on introducing new foods, available in one place from a trusted source. Studies now show that introducing a variety of foods into a baby’s diet is recommended, including peanut foods, if the infant is at risk for a peanut allergy. Always check with your baby’s doctor first!
New Online Hub Dedicated to Raising Awareness and Educating New Parents
McLean, Va. (April 30, 2020) — Today, FARE (Food Allergy Research & Education), the world’s leading food allergy advocacy organization and the largest private funder of food allergy research, announced the launch of a new resource geared at raising awareness of the benefits of introducing a variety of new foods to babies and educating people on how they might be able to help reduce the risk of developing food allergies.
Everyone with allergies has probably experienced skin-prick tests and other assessments to find out exactly what they are allergic to. Today there is a new “ology” called molecular allergology that is innovating how allergies are diagnosed and treated. A routine blood test combined with molecular diagnostics will allow physicians to identify, with great specificity, the component proteins to which a patient is allergic. This new approach will also help gauge where a patient falls on the spectrum of possible reactions, so they will know what restrictions need to be put in place.
Researchers estimate that in the US, more than 50 million adults and 26 million children suffer from allergies every year, with an estimated $18 billion annually in associated costs to the healthcare system and businesses—with no end in sight, as the number of individuals affected by allergies continues to rise.
Historically, standard clinical management for allergies involved assessment of a patient’s reactions and history, followed by skin-prick testing, and/or immunoassays of whole allergen-specific immunoglobulin E (sIgE). The emerging field of molecular allergology is innovating how allergies are diagnosed and treated. Today, a routine blood test coupled with molecular diagnostics can allow physicians to identify, with great specificity, the component proteins to which a patient is sensitized.